Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Polyplus-transfection licenses PEI to Roche for in-vitro transfection applications
March 2011
SHARING OPTIONS:

STRASBOURG, FranceóPolyplus-transfection SA, a privately held company developing innovative solutions for the delivery of nucleic acids in research, bioproduction and therapy, has granted Roche Glycart AG, a Swiss biotechnology company fully owned by Roche, a non-exclusive license to use its polyethylenimine (PEI) for in-vitro transfection applications for research purposes. The license will enable Roche Glycart AG to use this transfection reagent in its research to produce antibody-based products. Financial terms were not disclosed.  
 
"PEI-mediated transfection is clearly an essential research tool in this field," says Mark Bloomfield, CEO of Polyplus-transfection. "Our business relationship with Roche Glycart also demonstrates the significant value of our intellectual property rights in the field of PEI-mediated nucleic acid delivery for research purposes."

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.